Skip to main content
. 2020 Nov 23;2(4):149–155. doi: 10.2991/chi.k.201108.001

Table 2.

Commonly used management strategies for CART cell toxicities

CRS management strategy Mechanism Advantages Disadvantages
Supportive care Treats symptoms of hypotension and hypoxia with IV fluids, vasopressors, and positive pressure oxygen Effective in maintaining organ function and preventing further damage Does not address root cause
Tocilizumab Blocks IL-6-mediated effects; IL-6 is a key CRS-associated cytokine Rapidly reverses CRS, targets specific cytokines involved in CRS cascade Does not cross blood–brain barrier—ineffective for treating neurotoxicity
Steroids Nonspecific immunosuppression reduces inflammation Effective in many tocilizumab-refractory CRS cases Non-targeted immunosuppression may limit CART efficacy and persistence